The traditional approach to healthcare deal-making is undergoing a fundamental shift. As financial leverage becomes less effective and market volatility increases, operational due diligence (ODD) has emerged as a critical tool for investors seeking to validate and execute credible value creation strategies.
In a recent roundtable discussion hosted by European...
Nasdaq-listed STAAR Surgical, a designer, developer and manufacturer of implantable lenses for the eye, has announced that based on preliminary estimates by STAAR’s proxy solicitor, STAAR did not receive the necessary stockholder votes to approve the merger agreement with Switzerland-based Alcon.
In December 2025, Alcon, the largest eye care device company in the world, entered into an amended merger agreement with the board of STAAR, for US$30.75 per share - a total equity value of approximately US$1.6bn.
Broadwood Partners, owner of 30.2% of STAAR’s shares, recommended shareholders vote against a proposed takeover by...
